Forsythin phospholipid complex as well as preparation method and application thereof
By combining with phospholipids, the bioavailability and local efficacy of forsythiatin has been improved, and its application restriction in respiratory and urinary system diseases has been solved, achieving efficient anti-inflammatory effects and long-term delivery in the lungs and bladder .
Patent Information
- Application Number
- CN202410977040.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-19
Smart Images

Figure BDA0004955793300000081 
Figure BDA0004955793300000091 
Figure HDA0004955793420000011
Abstract
Description
Technical Field
[0001] The present invention relates to a forsythiaside phospholipid complex and a preparation method and application thereof. Specifically, the present invention relates to a forsythiaside phospholipid complex using phospholipid as an auxiliary material and a preparation method thereof, and also relates to the application of the forsythiaside phospholipid complex in the preparation of a drug for preventing and / or treating urinary system or respiratory system diseases. The present invention belongs to the field of medical technology. Background Art
[0002] Forsythia suspensa is a famous traditional Chinese medicine with the effects of clearing away heat and detoxifying, reducing swelling and dispersing knots, and evacuating wind-heat. It is often used to treat respiratory inflammation and oral ulcers and is known as the "holy medicine for sores". Forsythia suspensa is one of the main active ingredients of Forsythia suspensa. The Chinese Pharmacopoeia stipulates that the content of forsythia suspensa in Forsythia suspensa must not be less than 0.15%. At present, many studies have shown that forsythia suspensa has anti-inflammatory, antiviral and antioxidant capabilities. However, due to the poor solubility of forsythia suspensa in water, low solubility and limited oral bioavailability, the development and application of forsythia suspensa products are limited.
[0003] In the treatment of local diseases such as the respiratory and urinary systems, tissue drug distribution is directly related to local efficacy. Improving the tissue drug distribution of drugs can significantly improve the local efficacy of drugs. In addition, local administration can increase the tissue / plasma concentration ratio of drugs by 10 to 100 times, indicating that local administration can increase the target tissue exposure of drugs and prolong the local anti-inflammatory effect. At present, the method of adding polymer excipients to prepare drugs into nanoparticles is usually used to improve the solubility of poorly soluble drugs and achieve local sustained release, but the biocompatibility of polymer excipients themselves is unknown, which may lead to potential in vivo toxicity. In comparison, phospholipid materials have good biocompatibility, and a large number of liposome preparations using phospholipids as excipients have entered clinical application. However, liposomes usually have disadvantages such as low drug loading, complex preparation process, and poor stability. Therefore, it is necessary to develop new forsythiaside preparation technology and drug delivery system with clinical application potential. Summary of the invention
[0004] The object of the present invention is to provide a forsythiaside phospholipid complex with phospholipid as an auxiliary material and a preparation method thereof, wherein the preparation can improve the lung and bladder bioavailability of forsythiaside, thereby improving its anti-inflammatory effect in the lung / bladder and prolonging the action time.
[0005] In order to achieve the above object, the present invention adopts the following technical means:
[0006] The forsythiaside phospholipid complex of the present invention comprises forsythiaside and phospholipid, wherein the forsythiaside and phospholipid are compounded through intermolecular non-covalent bonds, and the mass ratio of the forsythiaside to the phospholipid is 1:(1-10), preferably 1:(1-4); the forsythiaside phospholipid complex is prepared by the following method: forsythiaside and phospholipid are weighed at a mass ratio of 1:(1-10), preferably 1:(1-4), and an organic solvent is added to dissolve them, and then they are mixed evenly; compounding is performed at a temperature of 30-60°C, and the reaction time is 0.5-4 hours, preferably 1.5-2.5 hours, and after the reaction is completed, cholesterol is added until dissolved, and then vacuum rotary evaporation is performed, and a redissolution solvent is added, and after filtering through an organic microporous filter membrane, rotary evaporation is performed again, and vacuum drying is performed to obtain the forsythiaside phospholipid complex.
[0007] Among them, preferably, the phospholipid is one of soybean lecithin, egg yolk lecithin, dipalmitoylphosphatidylcholine (DPPC), and distearoylphosphatidylcholine (DSPC), the organic solvent is a methanol-chloroform solution mixed in a volume ratio of 1:1, and the re-dissolution solvent is dichloromethane.
[0008] Among them, preferably, the mass ratio of cholesterol to phospholipid is 1:2.
[0009] Furthermore, the present invention also proposes the use of the forsythiaside phospholipid complex in the preparation of a drug for treating interstitial cystitis or inflammation caused by viruses or bacteria in lung infection.
[0010] Preferably, the drug is an oral preparation, a suspension for topical administration or an inhalable aerosol.
[0011] Furthermore, the present invention provides an oral preparation containing the forsythiaside phospholipid complex, which is prepared into an oral preparation by conventional pharmaceutical techniques.
[0012] Furthermore, the present invention provides a suspension containing forsythiaside phospholipid complex, which is prepared by the following method:
[0013] After the forsythiaside phospholipid complex is added to physiological saline or PBS for hydration, the particle size is controlled by ultrasonic dispersion, high-pressure homogenization, microfluidics or other particle size control methods, and then high-pressure sterilization or filtration sterilization is performed to form a forsythiaside phospholipid complex suspension;
[0014] Preferably, the mass ratio of forsythiaside phospholipid complex to physiological saline or PBS is 1:100;
[0015] Preferably, the particle size distribution range of the suspension of the forsythiaside phospholipid complex is 50-1000 nm, and the median particle size range is 100-350 nm, preferably 100-250 nm.
[0016] Furthermore, the present invention provides an inhalable aerosol containing the forsythiaside phospholipid complex, which is formed by passing the suspension of the forsythiaside phospholipid complex through an air compression atomizer or a vibrating mesh atomizer to form the inhalable aerosol.
[0017] Furthermore, the present invention proposes the use of the oral preparation, the suspension, and the inhalable aerosol in the preparation of a drug for treating interstitial cystitis or inflammation caused by viruses or bacteria in lung infections.
[0018] The forsythiaside phospholipid complex suspension is dripped by a syringe or formed into an inhalable aerosol by a commercial nebulizer, without affecting the physical and chemical properties of the complex itself. The preparation can significantly improve the lung bioavailability of the drug after pulmonary administration, and compared with the original drug suspension, significantly improve the anti-inflammatory effect of inflammation caused by lung infection viruses and bacteria. After the forsythiaside phospholipid complex suspension is dripped into the bladder, the bioavailability of the drug in the bladder tissue is significantly improved, and the efficacy of the drug against interstitial cystitis is improved.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] The invention discloses a method for preparing a forsythiaside phospholipid complex. The invention directly prepares the forsythiaside phospholipid complex into an oral preparation, or the complex can be prepared into a suspension, which can be sterilized and used as a suspension for atomization inhalation, and efficiently delivered to the lungs, or can be delivered to the bladder via intravesical instillation.
[0021] Although there are many reports on the preparation method of drug-phospholipid complexes, that is, the drug and phospholipids are dissolved in an organic solvent and reacted to form a complex, and a dry powder can be obtained by vacuum drying under reduced pressure. However, different phospholipid complexes have different stabilities, and only stable phospholipid complexes have application prospects.
[0022] The forsythiaside phospholipid complex has not been reported in the literature before. The inventors of the present invention unexpectedly discovered that the forsythiaside phospholipid complex powder prepared can obtain a storage-stable suspension after stirring and particle size control during the hydration process. After the suspension is sterilized by high pressure, the particle size of the suspension and the properties of the phospholipid complex itself do not change. The suspension obtained by sterilization is suitable for intravesical instillation for the treatment of interstitial cystitis; the suspension obtained by sterilization can also be used for atomization inhalation administration, and the atomization process also does not affect the particle size of the suspension and the properties of the phospholipid complex itself.
[0023] The poorly soluble drug forsythin usually has low bioavailability due to its low solubility, which limits its efficacy in interstitial cystitis. When the original drug suspension is administered intravesically, forsythin has poor affinity for bladder tissue, the drug is poorly distributed in the bladder, and the efficacy is poor. However, the phospholipid complex improves the drug's affinity for bladder tissue, thereby improving its distribution in bladder tissue cells, thereby improving its efficacy in treating interstitial cystitis.
[0024] Similarly, due to its poor affinity to lung tissue, forsythin restricts its drug distribution and therapeutic effect in the lungs, thus limiting its clinical application in the treatment of respiratory diseases. The present invention unexpectedly found that the oral preparation of forsythin phospholipid complex is beneficial to improve its lung anti-inflammatory efficacy. Indeed, the results of in vivo pharmacokinetics and tissue distribution showed that the plasma bioavailability (AUC) of the phospholipid complex was 2.03 times that of the original drug, while the AUC of the former in the lung tissue and immune cells in the lung epithelial lining fluid was 3.66 times and 7.51 times that of the latter, respectively, indicating that the forsythin phospholipid complex improves the drug's affinity to lung tissue, thereby helping to improve the drug's lung distribution and local therapeutic efficacy.
[0025] The present invention further found that compared with oral preparations, the phospholipid complexes administered by lung administration significantly increased and prolonged the drug content of the drug in the lung tissue. The latter's AUC of immune cells in lung tissue and lung epithelial lining fluid were 39.61 and 197.86 times that of the oral preparation phospholipid complex group. In terms of anti-inflammatory efficacy in mouse lungs and improving the survival rate of mice with acute respiratory distress syndrome, the efficacy of low-dose pulmonary administration cannot be achieved by increasing the oral or injection dose, that is, the efficacy of pulmonary administration of forsythiaside phospholipid complexes is irreplaceable by other systemic administration routes.
[0026] In addition, the present invention also found that compared with the forsythiaside phospholipid complex suspension, the forsythiaside original drug suspension has a weaker effect on pneumonia caused by pseudoviral or bacterial infection after pulmonary administration. That is to say, the anti-inflammatory effect of forsythiaside pulmonary administration is due to the lung tissue affinity of the forsythiaside phospholipid complex, rather than due to local pulmonary administration.
[0027] Compared with liposome preparations, the drug preparation based on phospholipid complex prepared by the present invention has the advantages of high drug loading, good stability, simple preparation method, etc. Drug-phospholipid complex is a new type of phospholipid nanoparticle prepared by reacting phospholipids with natural products in an organic solvent. It has many similarities with traditional liposomes and also shows unique advantages in physical stability, encapsulation efficiency and technical amplification. In addition, forsythiaside phospholipid complex can also be prepared into inhalable microparticles by spray drying, and delivered to the lungs by dry powder inhalation to exert therapeutic effects, while maintaining the physical and chemical properties of phospholipid complex. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The particle size distribution results and transmission electron microscopy images of the Forsythiaside Phospholipid Complex (FPC) suspension after hydration dispersion / sterilization and atomization by a nebulizer.
[0029] Figure 2 The in vitro release curves of Forsythiaside (FOR) suspension, Forsythiaside phospholipid complex (FPC) and Forsythiaside physical mixture suspension in 1% SDS-PBS (n=3, mean±SD).
[0030] Figure 3A The uptake kinetic curves of Forsythiaside (FOR) and Forsythiaside phospholipid complex (FPC) in RAW264.7 cells.
[0031] Figure 3B The changes of lung tissue affinity constant (Kp) of FPC and FOR on isolated lung tissue over time.
[0032] Figure 3C The desorption kinetic curves of FPC and FOR on isolated lung tissue (n=3, mean±standard deviation).
[0033] Figure 4A This is the inhibition rate curve of FPC and FOR at different concentrations on the inflammatory factor IL-6 in RAW264.7 cells after lipopolysaccharide (LPS) stimulation.
[0034] Figure 4B The figure shows the inhibition rate curve of inflammatory factor IL-6 by FPC and FOR at different concentrations on RAW264.7 cells after stimulation with polyinosinic-polycytidylic acid complex (PIC) (n=3, mean±standard deviation).
[0035] Figure 5 Comparison of the NO inhibition rate of FPC and FOR at different concentrations on RAW264.7 cells after LPS stimulation (A), the antioxidant capacity comparison (B) and the ROS fluorescence image (C) (n=3, mean±SD).
[0036] Figure 6 Drug distribution in (A) lung epithelial lining fluid (ELF), (B) immune cells in lung epithelial lining fluid, (C) lung tissue, and (D) plasma at different time points in mice with acute lung injury who were injected with forsythia glycoside phospholipid complex suspension (FPC) or intraperitoneally administered forsythia glycoside (FOR) suspension via lung and intraperitoneal injection. (E) Lung / plasma drug concentration ratio at 1, 3, and 5 hours in mice with acute lung injury who were injected with FPC or intraperitoneally administered FOR. (n=6, mean ± SD)
[0037] Figure 7Evaluation of the dose-dependent anti-inflammatory efficacy of forsythiaside phospholipid complex suspension (FPC) and forsythiaside (FOR) suspension in mice with lipopolysaccharide (LPS)-induced acute lung injury after intrapulmonary and intraperitoneal injection. (A) Changes in total protein content in mouse bronchoalveolar lavage fluid (BALF) after administration. (B) Immune cell counts in mouse bronchoalveolar lavage fluid after administration. (C) Changes in cyclic adenosine monophosphate (cAMP) content in mouse lung tissue after administration. Relative contents of inflammatory factors (D) TNF-α, (E) IL-6, and (F) IL-1β in mouse bronchoalveolar lavage fluid after administration. (G) HE staining of lung tissue sections (magnification 10, 20 times). (H) Lung injury score. (n=6, mean ± SD)
[0038] Figure 8 Evaluation of the time-dependent anti-inflammatory efficacy of forsythiaside phospholipid complex suspension (FPC) and forsythiaside (FOR) suspension in lipopolysaccharide (LPS)-induced acute lung injury by pulmonary and intraperitoneal injection. (A) Experimental time diagram of mouse dosing and sampling. (B) Changes in total protein content in mouse bronchoalveolar lavage fluid (BALF) after administration. (C) Immune cell counts in mouse bronchoalveolar lavage fluid after administration. (D) Lung injury score. Relative contents of inflammatory factors (E) TNF-α, (F) IL-6, and (G) IL-1β in mouse bronchoalveolar lavage fluid after administration. (H) HE staining of lung tissue sections (magnification 10, 20 times). (n=6, mean ± SD)
[0039] Fig. 9 This is a dose-dependent evaluation of the anti-inflammatory efficacy of forsythiaside phospholipid complex suspension (FPC) and forsythiaside (FOR) suspension in mice with acute lung injury induced by polyinosinic-polycytidylic acid complex Poly(I:C) (PIC) after pulmonary and oral administration. (A) Changes in total protein content in mouse bronchoalveolar lavage fluid (BALF) after administration. (B) Immune cell counts in mouse bronchoalveolar lavage fluid after administration. (C) Lung injury score. Relative contents of inflammatory factors (D) TNF-α, (E) IL-6, and (F) IL-1β in mouse bronchoalveolar lavage fluid after administration. (G) HE staining of lung tissue sections (magnification 10, 20 times). (n=6, mean ± SD)
[0040] Fig.10 The changes in the survival rate of mice after pulmonary and intraperitoneal injection of forsythia glycoside phospholipid complex suspension (FPC) and intraperitoneal injection of forsythia glycoside (FOR) suspension in the LPS-induced acute respiratory distress syndrome (ARDS) model. (A) Survival rate change curve of mice within 7 days. (B) Body weight changes of mice within 7 days. (C) Lung injury score. (D) HE staining of lung tissue sections (magnification 10, 20 times). (n = 6, mean ± standard deviation)
[0041] Fig.11To investigate the effects of oral and intravesical administration of forsythiaside (FOR) suspension and forsythiaside phospholipid complex suspension (FPC) on the bladder wall permeability of rats in the cyclophosphamide (CYP)-induced interstitial cystitis (IC) model. (n=5, mean ± SD) DETAILED DESCRIPTION
[0042] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.
[0043] Example 1 Preparation and optimization of forsythiaside phospholipid complex
[0044] Forsythiaside and lecithin or DPPC are dissolved in an organic solvent in different mass ratios and heated under reflux to generate the product. The organic solvent is completely removed by reduced pressure distillation combined with vacuum drying to obtain Forsythiaside phospholipid complex dry powder. Since Forsythiaside is insoluble in dichloromethane, while dipalmitoylphosphatidylcholine (DPPC) is soluble in dichloromethane, the phospholipid complex formed by the two is also soluble in dichloromethane. Therefore, dichloromethane is selected as the re-dissolution solvent to extract the Forsythiaside phospholipid complex and calculate the complex rate; after re-dissolution, extraction and filtration with dichloromethane, the ratio of the phospholipid complex content in the filtrate to the total input is determined. The results show that:
[0045] 1) Since forsythiaside is slightly soluble in organic solvents such as methanol and ethanol, but can be completely dissolved in a methanol-chloroform (1:1) mixed solvent, and phospholipids can also be completely dissolved in the mixed solvent, a methanol-chloroform (1:1) mixed solution was selected as the reaction solvent. When the mass ratio of forsythiaside to phospholipids was 1:(1-10), the recombination rate in a methanol-chloroform (1:1) solution at 45°C for 2 hours was investigated; the mass ratio of 1:(1-4) had a higher recombination rate, and the recombination rate was the highest when the mass ratio was 1:3.
[0046] 2) When the mass ratio of forsythiaside to DPPC was 1:3, the reaction time in methanol-chloroform (1:1) solution at 45°C was 0.5, 1, 2, 3, and 4 hours, respectively. The recombination rate first increased and then decreased with the extension of reaction time. The recombination rate was higher in 1-2 hours, and the highest in 2 hours.
[0047] 3) When the mass ratio of forsythiaside to DPPC was 1:3, the recombination rate increased first and then decreased with the increase of reaction temperature in methanol-chloroform (1:1) solution at 30, 45, and 60°C for 2 hours, and the recombination rate was the highest at 45°C.
[0048] Example 2 Preparation of Forsythiaside Phospholipid Complex Suspension (FPC)
[0049] Weigh 8 mg of forsythiaside and 24 mg of DPPC (or soybean lecithin) in a mass ratio of 1:3, dissolve in 4 mL of methanol-chloroform (volume ratio 1:1) solution, stir in the dark at 45°C and 500 rpm for 2 hours, add 12 mg of cholesterol (the mass ratio of cholesterol to phospholipid is 1:2) after the reaction is completed, ultrasonicate for 30 seconds, and then rotary evaporate at 100 rpm for 15 minutes, add 4 mL of dichloromethane, filter through a 0.22 μm organic microporous filter membrane, and rotary evaporate at 100 rpm for 15 minutes again. After vacuum drying overnight, the forsythiaside phospholipid complex dry powder is obtained.
[0050] 1) Add 4 mL of saline or PBS to the DPPC phospholipid complex dry powder (the mass ratio of dry powder to saline or PBS is 1:100), heat and ultrasonicate at 60°C for hydration, and then ultrasonicate with a 300W probe for 10 minutes in an ice bath (on for 3 seconds and off for 7 seconds in one cycle) to obtain a suspension. After the suspension is sterilized in an autoclave for 1 hour, a suspension of forsythiaside phospholipid complex for nebulized inhalation is obtained.
[0051] The average particle size of the suspension was 119.0±6.9nm, PDI was 0.228±0.027, potential was -10.0±0.5mV, encapsulation efficiency was 85.15%, and drug loading was 21.33%; the particle size of the suspension collected after sterilization and atomization by Aerogen Solo atomizer also did not change significantly. TEM images also showed that the phospholipid complex maintained a similar nanostructure before and after atomization ( Figure 1 ). In addition, after the suspension was stored at 4°C for 14 days, the particle size and PDI results did not change significantly, which were 116.3±1.3nm and 0.204±0.042, respectively. The potential changed to -16.1±0.8mV. The increase in the absolute value of the potential indicated that its structure tended to be stable. The phospholipid complex was still able to maintain a good dispersion state after being gently mixed in water, indicating that it had good storage stability.
[0052] 2) Physiological saline or PBS was added to the DPPC phospholipid complex dry powder and heated and ultrasonically hydrated at 60°C, and high-pressure homogenization was performed 10 times at a pressure of 500 bar to obtain a suspension. The average particle size of the suspension was 157.6±10.1nm. In addition, after the suspension was stored at 4°C for 14 days, the particle size became 139.0±1.4nm. Compared with the probe ultrasonic method, the suspension obtained by the high-pressure homogenization method has an equilibrium period.
[0053] 3) Add physiological saline or PBS to the DPPC phospholipid complex dry powder and heat it at 60°C for ultrasonic hydration, then ultrasonicate it with a 300w probe for 10 minutes in an ice bath (on for 3 seconds and off for 7 seconds in one cycle) to obtain a suspension. The average particle size of the suspension is 139.6±3.5nm, the PDI is 0.200±0.006, the potential is -2.6±0.1mV, the encapsulation efficiency is 97.08%, and the drug loading is 24.57%. In addition, after the suspension was stored at 4°C for 14 days, the particle size and PDI results did not change significantly. The phospholipid complex can still maintain a good dispersion state after gently mixing in water, indicating that it has good storage stability.
[0054] Experimental Example 1 Characterization and in vitro release evaluation of forsythiaside phospholipid complex (FPC, prepared in Example 2) suspension
[0055] (1) The aerodynamic properties of the phospholipid complex suspension aerosol were verified using a next generation pharmaceutical impactor (NGI). Specifically, the NGI was first placed in a 4°C refrigerator for precooling for more than 1.5 hours. The NGI with glass fiber filter paper was assembled according to the instructions, and the flow rate was measured and adjusted to 15 L / min using an airflow meter. Then, 2 mL of FPC saline dilution or forsythiaside (FOR) suspension (forsythiaside original drug was diluted with saline) was added to the nebulizer cup, with a concentration of 0.5 mg / mL, and the nebulizer adapter was connected to the L-shaped artificial throat of the NGI. The nebulizer and vacuum pump were turned on at the same time. After the test was completed within the specified time, the vacuum pump and nebulizer were turned off. The NGI was turned on to observe whether the droplet state of each level of the NGI was normal. Then, 10 mL of 50% methanol-water was used to rinse the NGI and the forsythiaside active substance remaining in the components of the nebulizer. After the eluent was centrifuged at 12000rpm for 15 minutes, the supernatant was determined by HPLC to determine the content of forsythiaside in each level. Finally, the calculation results were imported into the CITDAS data analysis system to calculate the total dose delivered (TD), fine particle fraction (FPF), mass median particle diameter (MMAD), and geometric standard deviation (GSD) to characterize the difference in aerodynamic performance between forsythiaside phospholipid complex and forsythiaside physical suspension. The results showed that compared with the physical mixture, forsythiaside phospholipid complex exhibited better aerodynamic properties. Compared with FOR, the FPC aerosol had a higher TD, a smaller MMAD, a larger GSD, and a higher FPF, indicating that the nanoscale phospholipid complex had a smaller aerodynamic particle size when forming atomized droplets than the physical suspension with a larger particle size, and was therefore more easily deposited in the deep lung (Table 1).
[0056] Table 1 Aerodynamic properties of aerosols after nebulization of forsythiaside phospholipid complex (FPC) and forsythiaside (FOR) suspensions (Mean±SD, n=3).
[0057]
[0058]
[0059] (2) The in vitro release of forsythiaside phospholipid complex suspension (FPC) was evaluated by dialysis method, and the differences in drug release between FPC and forsythiaside (FOR) suspension and physical mixture of forsythiaside, DPPC and cholesterol in the ratio of 1:3:2 were compared. Specifically, 2 mL, 1 mg / mL forsythiaside phospholipid complex suspension, forsythiaside suspension and physical mixture suspension were respectively added into 3500Da dialysis bags (n=3), and 200 mL 1% SDS-PBS was used as the release medium. The release was carried out at 37°C and 200 rpm. 0.5 mL of the drug-containing release medium was taken out at 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours after the start of release, and the same volume was immediately filled with blank release medium. The drug-containing release medium was diluted with 0.5 mL of methanol and centrifuged at 12000 rpm for 15 minutes. The supernatant was taken and the drug amount at each time point was determined on HPLC and the release curve was drawn. The results showed that the average cumulative release rate of forsythiaside raw material in 24 hours was only 49.21%, which may be related to the strong hydrophobicity of forsythiaside raw material and the large particle size of the drug. The average cumulative release rate of the physical mixture increased to 56.00%, which may be due to the solubilization effect of the excipients phospholipids and cholesterol. The average cumulative release rate of forsythiaside phospholipid complex FPC within 6 hours was 84.93%, which significantly improved the release rate and cumulative release degree of forsythiaside ( Figure 2 ). After the poorly soluble drug Forsythiaside was prepared into a phospholipid complex, the particle size became significantly smaller. According to the Ostwald-Freundlich equation, when the drug particle size is less than 1 μm, the solubility of the drug will increase with the decrease of the particle size, and according to the Noyes-Whitney equation, the smaller the particle size of the drug, the larger the specific surface area, and the faster the dissolution rate of the drug. Therefore, compared with the Forsythiaside original drug and the physical mixture, the Forsythiaside phospholipid complex has higher solubility, faster release rate and greater cumulative dissolution.
[0060] Experimental Example 2 Determination of the uptake of forsythiaside phospholipid complex (FPC, prepared in Example 2) suspension on RAW 264.7 cells and adsorption and desorption kinetics on isolated lung tissue
[0061] (1) Before conducting cell experiments, the safe concentrations of forsythiaside (FOR) and forsythiaside phospholipid complex (FPC) in RAW264.7 cells were first determined by the MTT method. The results showed that FPC had no cytotoxicity at concentrations of 0.05-100 μM, so the maximum dose of 100 μM was selected for the uptake experiment.
[0062] (2) The uptake kinetics of forsythiaside phospholipid complex (FPC) and forsythiaside (FOR) in mononuclear macrophage RAW 264.7 cells after lipopolysaccharide (LPS) stimulation were compared to verify the difference between the phospholipid complex and the API in terms of cellular uptake behavior. Specifically, RAW 264.7 cells were cultured at 1×10 6 / well were seeded in 6-well plates, cultured at 37°C, 5% CO2 for 24 hours, stimulated with 100 ng / mL LPS for 24 hours, then the original culture medium was aspirated and fresh drug-containing culture medium (the concentrations of forsythia glycoside phospholipid complex and forsythia glycoside were both 100 μM) was added. After incubation for 0.5, 1, 2, and 4 hours, the supernatant was discarded, washed three times with PBS buffer, and RIPA cell lysis buffer was added. Then all cells were collected with a cell scraper, transferred to a centrifuge tube, added with methanol, sonicated with a 100w power probe for 1 minute, oscillated for extraction for 3 minutes, and then centrifuged at 12000rpm for 10 minutes. The supernatant was taken for HPLC detection. The results showed that after forsythia glycoside was prepared into a phospholipid complex, the uptake amount and uptake rate on RAW 264.7 cells were higher than those of the raw drug forsythia glycoside, indicating that the phospholipid complex may have the effect of improving cell uptake, which may be due to the increase in drug lipophilicity after preparation into a phospholipid complex ( Figure 3A ).
[0063] (3) Compare the affinity of forsythiaside phospholipid complex (FPC) and forsythiaside (FOR) on isolated lung tissue to verify the difference between the phospholipid complex and the raw material in terms of lung tissue affinity. The isolated lung tissue explant model was used to evaluate the tissue to buffer partition coefficient (Kp), Kp (C lung / C Buffer ) is used to reflect the distribution of drugs in lung tissue. The higher the Kp value, the greater the adsorption of drugs and the better the affinity with lung tissue. First, the adsorption kinetics experiment on isolated lung tissue was carried out. Specifically, fresh rat lung tissue was cut into about 1 mm 3About 100 mg of lung pieces and 0.9 mL of KREBS-RINGER buffer were added to each well of a 24-well plate. Then 100 μL of 1.5 mg / mL FPC or FOR suspension was added to the wells and blown evenly to make the final drug concentration in the wells 150 μg / mL. The 24-well plate was incubated at 37°C, and after 15, 30, 45, 60 or 120 minutes of incubation, 0.2 mL of buffer and lung pieces in the wells were collected respectively. The lung pieces were washed with physiological saline to remove the drugs attached to the surface, and then homogenized in a 50% methanol-water solution to extract the drugs inside. 0.2 mL of methanol was added to the buffer, and after ultrasonication, the supernatant was centrifuged at 12000 rpm for 5 minutes, and HPLC analysis was performed to obtain the buffer (C buffer , μg / mL) and lung tissue (C lung , μg / g lung tissue), and calculated the Kp value and plotted its time-varying curve; then the desorption kinetics experiment on the isolated lung tissue was conducted, specifically, the lung pieces were first incubated in a buffer containing FPC or FOR at a drug concentration of 150μg / mL for 60 minutes, washed with saline to remove the surface adsorbed drugs, and then transferred to 1mL blank buffer. After incubation at 37°C for 15, 30, 60 or 120 minutes, the lung pieces in the wells were collected, washed with saline to remove the drugs attached to the surface, and then homogenized in 50% methanol-water solution to extract the drugs inside, and then centrifuged at 12000rpm for 5 minutes and the supernatant was taken for HPLC analysis, and the drug concentration on the lung tissue was calculated and plotted over time. The results showed that after the drug was prepared into a phospholipid complex, its average Kp value at different time points increased from 0.76-1.42 to 1.17-1.51, and the desorption half-life was extended from 20.64 minutes of forsythiaside to 25.07 minutes. This result showed that preparing forsythiaside into a phospholipid complex increased its affinity for lung tissue and prolonged the retention time of forsythiaside in the lungs ( Figure 3B , C).
[0064] Experimental Example 3 Anti-inflammatory and antioxidant capacity test of forsythiaside phospholipid complex (FPC, prepared in Example 2) suspension on RAW 264.7 cells
[0065] (1) The levels of interleukin-6 (IL-6) in the supernatant of RAW 264.7 cells stimulated with lipopolysaccharide (LPS) or polyinosinic-polycytidylic acid (PIC) complex (PIC) were measured after adding forsythia phospholipid complex (FPC) or forsythia phospholipid complex (FOR) to compare the difference in the anti-inflammatory effect of FPC with that of FOR. Specifically, RAW264.7 cells in the logarithmic phase with good growth status were seeded into 96-well cell culture plates (cell density: 1×10 5Cells / well), incubated in the incubator for 12 hours to adhere to the wall, the culture medium was aspirated, and culture medium containing different concentrations of FOR or FPC (62.5, 12.5, 2.5, 0.5, 0.1, 0.02, 0.004 μM) was added. After 1 hour, 20 μL of LPS culture medium containing 1 μg / mL (incubation concentration 100 ng / mL) or 20 μL of PIC culture medium containing 200 μg / mL (incubation concentration 20 μg / mL) was added. After incubation for 12 hours, the supernatant was taken, diluted appropriately and tested according to the instructions of the IL-6 ELISA kit. Subsequently, the four-parameter fitting method was used to draw the inhibition rate curve of the drug on IL-6 at each concentration, and the half inhibition concentration (IC50) was calculated. The results showed that under the LPS model, the IC50 of FOR and FPC on the inflammatory factor IL-6 were 775.2 and 145.7 nM, respectively ( Figure 4A ), while the IC50 of FOR and FPC for inflammatory factor IL-6 in PIC model were 504.4 and 144.8 nM respectively ( Figure 4B ), the IC50 values of FPC in both models were smaller than those of FOR, indicating that the anti-inflammatory effect of forsythiaside was improved after it was prepared into phospholipid complex.
[0066] (2) The inflammatory mediator nitric oxide (NO) level in the supernatant of monocyte macrophages RAW 264.7 cells stimulated with lipopolysaccharide (LPS) was measured after adding forsythia phospholipid complex (FPC) or forsythia glycoside (FOR) to compare the difference in the anti-inflammatory effect of FPC with that of FOR. Specifically, RAW264.7 cells with good growth status were inoculated in 12-well plates (cell density: 5×10 5 cells / well), treated with different concentrations (4, 20, 100 μM) of FOR, FPC and positive drug dexamethasone (DEX, 100 μM) for 2 hours, and then stimulated with LPS (concentration 100 ng / ml) for 24 hours, collected the supernatant, and centrifuged at 10000 rpm for 5 minutes. The NO level was detected using a NO kit. The results showed that the inhibitory ability of FPC on NO was better than that of FOR at all concentrations, and there was a significant difference at 4 and 20 μM (P<0.05). In addition, the inhibitory ability of FPC at 100 μM was comparable to that of the positive drug DEX. It may be that after Forsythia glycosides were prepared as phospholipid complexes, the cellular uptake was increased, thereby showing better in vitro anti-inflammatory activity ( Figure 5 A).
[0067] (3) The reactive oxygen species (ROS) levels of lipopolysaccharide (LPS)-stimulated mononuclear macrophage RAW 264.7 cells were measured after adding forsythia phospholipid complex (FPC) or forsythia glycoside (FOR) suspension, and the differences in cellular antioxidant capacity between FPC and FOR were compared. RAW264.7 cells were treated with different concentrations of FPC or FOR (4, 20, 100 μM) and positive drug N-acetylcysteine (NAC) for 2 h, then stimulated with LPS for 30 min, and washed with blank medium three times. Subsequently, the cells were incubated with fluorescent probe DCFH-DA in the dark at 37°C for 30 min, and the blank medium was washed again three times, and then observed and photographed with a fluorescence microscope. The cells were then transferred to a black 96-well plate, and the intracellular ROS level was quantitatively detected using a fluorescence spectrophotometer. The results showed that the antioxidant capacity of FPC was better than that of FOR at all concentrations, and there was a significant difference at 4 and 20 μM (P<0.05). It may be that the phospholipid complex prepared by forsythiaside increased the cellular uptake, thus showing better in vitro antioxidant activity ( Figure 5 B, C).
[0068] Experimental Example 4 Evaluation of the pulmonary pharmacokinetics of forsythiaside phospholipid complex (FPC, prepared in Example 2) suspension
[0069] For drugs that exert anti-inflammatory effects in the lungs, the anti-inflammatory effects of the drugs are more related to the pulmonary bioavailability of the drugs than the plasma bioavailability, so it is necessary to clarify the pulmonary bioavailability of the drugs after pulmonary administration. The present invention compares the pulmonary pharmacokinetics of forsythia glycoside phospholipid complex suspension after pulmonary administration and intraperitoneal administration in mice with LPS-induced acute lung injury (ALI) model, and compares it with intraperitoneal administration of forsythia glycoside physical suspension, in order to explore the differences in pulmonary bioavailability between the two administration methods and the two dosage forms.
[0070] The specific experimental process is:
[0071] (1) Experimental operation of lung tissue distribution: First, the mouse ALI model was induced by tracheal instillation of LPS (0.5 mg / kg). The tracheal instillation method was improved on the basis of our previous method. Specifically, first, isoflurane was poured into the gas anesthesia device, the air pump was turned on and the flow rate was adjusted to 250 mL / min, the concentration was adjusted to 3, and the mouse was placed in the induction box. The mouse was anesthetized for about 2-3 minutes (it could not turn over), and then quickly placed on the tracheal drug delivery board, the light angle was adjusted, and a plastic tube containing isoflurane was used to fumigate the mouse nose tip for about 5 seconds. The mouse tongue was pinched with tweezers to find the trachea, and the tracheal drug delivery needle (22g) was immediately inserted into the trachea. The inner needle was pulled out, and 50 μL of the drug solution was dripped into the blue needle sleeve. If the trachea was inserted, the liquid level would drop. If the liquid level did not move, it meant that the trachea was not inserted and it needed to be re-anesthetized and inserted. After the drug delivery was completed, the mouse was rotated 3 times to ensure that the drug solution was evenly distributed. Then the mice were randomly divided into 3 groups. The first group of mice were given forsythia glycoside phospholipid complex suspension (FPC) by intratracheal instillation (IT) 2 hours after modeling, and the dosage was 2 mg / kg (calculated as forsythia glycoside); the second group of mice were given FPC by intraperitoneal injection (IP) 2 hours after modeling, and the dosage was 20 mg / kg (calculated as forsythia glycoside); the third group of mice were given forsythia glycoside original drug suspension by intraperitoneal injection 2 hours after modeling, and the dosage was 20 mg / kg (calculated as forsythia glycoside). The mice were euthanized at different time points after administration, and then about 200 μL of blood was taken from the heart and immediately centrifuged at 13000 rpm for 15 minutes, and 50 uL of supernatant was taken; after tracheal intubation, alveolar lavage fluid was collected, lavaged 3 times with 0.8 mL of normal saline, and the volume was fixed to obtain 2.0 mL of alveolar lavage fluid, and the alveolar lavage fluid was centrifuged at 3000 rpm for 15 minutes to separate cells and lavage fluid; the mouse lung tissue was removed, washed and weighed. All samples were aliquoted and stored at -80°C for further analysis.
[0072] (2) Sample processing:
[0073] ① Alveolar lavage fluid: centrifuge the alveolar lavage fluid at 3000rpm for 15 minutes, take 200μL of the supernatant and add 200μL of methanol, vortex for 5 minutes, centrifuge at 13000rpm for 15 minutes, and take 150μL of the supernatant to detect the concentration by LC-MS / MS.
[0074] ② Cells in bronchoalveolar lavage fluid: After discarding the supernatant of the bronchoalveolar lavage fluid, add 300 μL of methanol to the cell pellet at the bottom, disrupt the cells by ultrasonication at 100w for 15 minutes, vortex for 5 minutes, centrifuge at 13000rpm for 15 minutes, and take 150 μL of supernatant to detect the concentration by LC-MS / MS.
[0075] ③ Lung tissue: Add 500 μL of saline to the removed lung tissue, then add about 1 mL of methanol, make it up to 2 mL, add grinding balls and grind it with a grinder, vortex the obtained homogenate for 5 minutes, and then centrifuge it at 13000 rpm for 15 minutes. Take 100 μL of the supernatant, then add 30 μL of internal standard (formononetin 50 ng / mL) and 170 μL of methanol, centrifuge at 13000 rpm for 15 minutes, and take 120 μL of the supernatant to LC-MS / MS for concentration detection.
[0076] ④ Plasma: Add 30 μL of internal standard (formononetin 50 ng / mL) to the plasma sample, then add 220 μL of methanol, vortex for 5 minutes, centrifuge at 13000 rpm for 15 minutes, and take 120 μL of the supernatant to LC-MS / MS for concentration detection.
[0077] (3) Result analysis: After the acute lung injury model mice were given forsythiaside suspension or forsythiaside phospholipid complex suspension according to different administration methods, the pharmacokinetic data of drug content in plasma, alveolar lavage fluid, lavage fluid cells and lung tissue after lavage were shown in Figure 6 The results showed that the exposure of intraperitoneally injected FPC in lung tissue, immune cells in lung epithelial lining fluid and plasma was 3.66, 7.51 and 2.03 times that of the original drug FOR, respectively, indicating that the phospholipid complex is beneficial to improve the plasma bioavailability of the drug, achieve long circulation of the drug, and thus improve the bioavailability of the drug in the inflamed lung; and the pulmonary administration of the phospholipid complex significantly prolonged the exposure of the drug to the immune cells in the lung tissue and lung epithelial lining fluid, which was 39.61 and 197.86 times that of the intraperitoneal administration of the phospholipid complex group, respectively, indicating that the pulmonary administration of forsythiaside phospholipid complex can significantly improve the pulmonary bioavailability of forsythiaside and prolong the drug's action time in the lung. The ratio of the drug concentration in lung tissue and plasma (lung / blood ratio) can reflect the affinity of the drug to lung tissue. The results showed that there was almost no difference in the lung / blood ratio between FPC and FOR 1, 3, and 5 hours after intraperitoneal administration, but the lung / blood ratio after tracheal administration of FPC was 11.00-78.08 times that of intraperitoneal injection of FPC, indicating that tracheal administration can significantly increase the affinity of the drug to lung tissue.
[0078] Experimental Example 5 Evaluation of the anti-inflammatory efficacy of forsythiaside phospholipid complex (FPC, prepared in Example 2) suspension (FPC) in lipopolysaccharide (LPS)-induced acute lung injury (ALI)
[0079] The present invention adopts the ALI model induced by LPS instillation in mice trachea, and compares and evaluates the pulmonary anti-inflammatory efficacy of FPC and forsythia glycoside (FOR) suspension after tracheal instillation and intraperitoneal injection. Specifically: acute lung injury is induced by the method of LPS instillation in mice trachea. First, in order to evaluate the dose-dependent anti-inflammatory effect in vivo, the mice are divided into a normal saline control group (Ctrl), a model group (LPS), a budesonide positive control group (BUD), an FPC tracheal instillation group (IT-FPC), a forsythia glycoside suspension tracheal instillation group (IT-FOR), an FPC intraperitoneal injection group (IP-FPC), and a FOR intraperitoneal injection group (IP-FOR). Each mouse in the Ctrl group was given 50 μL of normal saline, the mice in the BUD group were given a 0.5 mg / kg intratracheal instillation of commercially available budesonide suspension for inhalation (Pulmicort Respules), the FPC IT group was given a 0.5, 1, 2 mg / kg intratracheal instillation, and the IP group was given a 10, 20, 40 mg / kg dose; the FOR IT group was given a 2 mg / kg dose, and the IP group was given a 20, 40 mg / kg dose. Three hours after administration, LPS (10 μg / mouse) was instilled into the trachea of mice except the NS group.
[0080] Subsequently, to evaluate the time dependence of the anti-inflammatory effect of the drug, mice were given intratracheal instillation of FPC (2 mg / kg) or intraperitoneal injection of FPC (20 mg / kg) or FOR (20 mg / kg), and then LPS (10 μg / mouse) was administered 3, 6, and 12 hours later. Finally, to evaluate the therapeutic anti-inflammatory effect, mice were given intratracheal instillation of LPS (10 μg / mouse), followed by tracheal instillation of FPC (2 mg / kg) or intraperitoneal injection of FPC (20 mg / kg) or FOR (20 mg / kg) 2 hours after intratracheal instillation of LPS (10 μg / mouse). Mice in all groups were euthanized 6 hours after LPS stimulation. The time sequence of drug administration and sampling is shown in Figure 8A. Subsequently, the alveolar lavage fluid was immediately collected and centrifuged at 3000 rpm for 15 minutes to separate the supernatant and the cell pellet. The cell pellet was resuspended in 60 μL of red blood cell lysis buffer, shaken for 5 minutes, centrifuged at 3000 rpm for 15 minutes, resuspended in PBS, and the total cell count was performed using a cell counter; the cell supernatant was diluted appropriately to determine the secretion and total protein content of tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), and interleukin 1β (IL-1β) in the supernatant. The contents of TNF-α, IL-6, and IL-1β were detected by the ELISA kit in the manufacturer's instructions, and the total protein content was detected by the BCA kit; at the same time, part of the mouse lung tissue was collected, fixed with a tissue fixative for more than 24 hours, and then embedded in paraffin, sliced and stained with HE: the slices were placed in xylene I for 20 minutes - xylene II for 20 minutes - anhydrous ethanol I for minutes - anhydrous ethanol II for 5 minutes - 75% alcohol for 5 minutes, rinsed with tap water, and stained with hematoxylin: the slices were dyed with hematoxylin stain for 3-5 minutes, washed with tap water, differentiated with differentiation solution, washed with tap water, blued with blueing solution, rinsed with running water, and then stained with eosin: the slices were placed in 85% and 95% gradient precipitate in sequence. The sections were dehydrated with ethanol for 5 minutes each, stained with eosin stain for 5 minutes, and finally dehydrated and sealed: the sections were placed in anhydrous ethanol I for 5 minutes - anhydrous ethanol II for 5 minutes - anhydrous ethanol III for 5 minutes - xylene I for 5 minutes - xylene II for 5 minutes to make them transparent, sealed with neutral gum, examined under a microscope, and image acquisition and analysis were performed. Subsequently, tissue damage was evaluated using a standardized lung injury scoring system to obtain a histological score for lung injury; 100 mg of mouse lung tissue was taken, 0.5 mL of normal saline was added, and ground with a tissue grinder. Subsequently, the homogenate was centrifuged at 12000 rpm for 15 minutes, and the supernatant was diluted appropriately and the cAMP content in the lung tissue was detected using a cyclic adenosine monophosphate (cAMP) ELISA kit.
[0081] The anti-inflammatory effects of different administration methods and different doses of FPC and FOR on LPS-induced ALI are shown in Figure 4. First, the total protein content and total cell count of bronchoalveolar lavage fluid are two key indicators to measure the severity of lung inflammation. Compared with the control group, the total protein content in the bronchoalveolar lavage fluid of LPS-induced ALI mice ( Figure 7 A) and total cell number ( Figure 7 B) increased significantly by 3 and 12 times, indicating the deepening of pulmonary edema and inflammation; at the same time, the pulmonary inflammation in ALI is mediated by proinflammatory cytokines, which may cause ALI. Common proinflammatory cytokines include TNF-α, IL-6, and IL1β. Compared with the control group, the levels of these three indicators in the alveolar lavage fluid were also significantly higher than those in the control group ( Figure 7DF); in addition, cyclic adenosine monophosphate (cAMP) is an intracellular second messenger that can reduce the activity of multiple signaling pathways involved in inflammation. The cAMP level in the lung tissue of the LPS model group was 33.66% lower than that of the control group, reflecting the generation of inflammation ( Figure 7 C). After the administration of budesonide or forsythiaside, the total protein content, total cell number and various inflammatory factors decreased compared with the LPS model group, while forsythiaside, as a natural phosphodiesterase inhibitor, increased the cAMP level in lung tissue by inhibiting PDE4. Among them, the anti-inflammatory effect of tracheally administered FPC at doses of 0.5, 1, and 2 mg / kg was dose-dependent, and the anti-inflammatory effect was best at a dose of 2 mg / kg. The total protein content and total cell number were reduced by 38.75% and 59.29% respectively compared with the LPS model group, TNF-α, IL-6, and IL1β were reduced by 52.85%, 62.00%, and 49.36% respectively, and cAMP increased by 17.70%. It was significantly different from tracheally administered FOR at the same dose (P<0.001), indicating that the formation of nano-scale phospholipid complexes is more conducive to the anti-inflammatory effect of Forsythia glycosides in the lungs, which may be related to the fact that phospholipid complexes with smaller particle sizes reduce mucus clearance and increase the uptake of pulmonary immune cells and epithelial cells. The physical suspension formed by simply adding phospholipids and cholesterol to Forsythia glycosides only has a limited solubilizing effect on Forsythia glycosides, and cannot effectively reduce the particle size of Forsythia glycoside crystals, resulting in limited bioavailability. Therefore, its effect after inhalation is not as good as that of phospholipid complexes. Compared with tracheal administration, the anti-inflammatory effect of FPC injected intraperitoneally was weaker, but still better than FOR injected intraperitoneally. In terms of total protein content, total cell number, TNF-α, IL-6, and IL1β, FPC injected intraperitoneally showed similar anti-inflammatory effects at 20 mg / kg and 40 mg / kg, indicating that the maximum platform range of the effective dose had been reached. Compared with the LPS model group, the total protein content and total cell number of 40 mg / kg FPC (IP) were reduced by 55.8% and 33.38%, respectively, TNF-α, IL-6, and IL1β were reduced by 35.88%, 40.41%, and 43.84%, respectively, and cAMP increased by 5.94%, all of which were not more significant than FPC (IT) 2 mg / kg, indicating that tracheal administration can exert better lung anti-inflammatory effects than intraperitoneal injection, and the high-dose intraperitoneal injection group cannot achieve the efficacy of the low-dose tracheal administration group, proving the irreplaceable nature of tracheal administration. The lung injury protection results shown by the pathological sections are consistent with the results reflected by the above indicators ( Figure 7 G, H).
[0082] To further clarify the difference in the duration of the pharmacodynamic effect of the phospholipid complex FPC after intratracheal and intraperitoneal injection compared with the original drug FOR, a time-dependent study of the anti-inflammatory effect was conducted. Figure 8 As shown. The results showed that the intraperitoneal injection of FOR for 12 hours had no significant difference with the LPS model group in reducing the total cell number and inhibiting the levels of TNF-α, IL-6, and IL1β in the alveolar lavage fluid (P>0.05), indicating that its anti-inflammatory effect can only last for 6 hours at most, while FPC was effective at 3, 6, and 12 hours of prevention by intraperitoneal administration, and there was still a significant difference with the LPS model group at 12 hours (P<0.001), and there was a significant difference with FOR in reducing the total cell number and inhibiting the levels of TNF-α and IL-6 in the alveolar lavage fluid (P<0.01). The efficacy of FPC administered by trachea can also be maintained for 12 hours, and there is a significant difference with the FOR intraperitoneal injection group at 12 hours (P<0.001); in addition, in terms of therapeutic effect, FPC administered by trachea showed the best anti-inflammatory effect among all indicators, and the therapeutic effect of FPC injected by intraperitoneal injection was better than that of FOR. The protective effect of lung injury shown by the pathological section results is consistent with the results reflected by the above indicators. Figure 6 As shown in Table 2, the improvement of lung bioavailability significantly enhanced the intensity of the anti-inflammatory effect of Forsythiaside in the lungs and prolonged the duration of action.
[0083] Experimental Example 6 Evaluation of the anti-inflammatory efficacy of forsythiaside phospholipid complex (FPC, prepared in Example 2) suspension (FPC) in virus-like acute lung injury (ALI) induced by polyinosinic-polycytidylic acid complex Poly (I:C) (PIC)
[0084] The present invention uses a virus-like ALI model induced by tracheal instillation of PIC in mice to compare and evaluate the lung anti-inflammatory efficacy of FPC and FOR after tracheal instillation and intragastric administration. Specifically, the mice were divided into a normal saline control group (Ctrl), a model group (PIC), a dexamethasone positive control group (DEX), an FPC tracheal instillation group (IT-FPC), a forsythiaside tracheal instillation group (IT-FOR), an FPC intragastric instillation group (IG-FPC), and a FOR intragastric instillation group (IG-FOR). Each mouse in the Ctrl group was given 50 μL of normal saline, and the positive drug dexamethasone was intraperitoneally injected at 5 mg / kg. The FPC IT group was given at 0.02, 0.1, 0.5, and 1 mg / kg, and the IG group was given at 20 mg / kg. The FOR (IT group was given at 1 mg / kg, and the IG group was given at 20 mg / kg. Three hours after administration, except for the NS group, PIC (120 μg / mouse) was instilled into the trachea of the mice. All mice in all groups were euthanized 24 hours after PIC stimulation. The time sequence of drug administration and sampling is shown in Figure 6A. Subsequently, the alveolar lavage fluid was immediately collected and centrifuged at 3000rpm for 15 minutes to separate the supernatant and the cell pellet. The cell pellet was resuspended in 60μL of red blood cell lysis buffer, shaken for 5 minutes, centrifuged at 3000rpm for 15 minutes, resuspended in PBS, and the total cell count was performed using a cell counter; the cell supernatant was diluted appropriately to determine the secretion and total protein content of tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), and interleukin 1β (IL-1β) in the supernatant. The content of TNF-α, IL-6, and IL-1β was detected by the ELISA kit specified in the manufacturer's instructions, and the total protein content was detected by the BCA kit; at the same time, part of the mouse lung tissue was collected, fixed with tissue fixative for more than 24 hours, and then embedded in paraffin. After sectioning, HE staining was performed, the slides were sealed, examined under a microscope, and image acquisition and analysis were performed. Subsequently, tissue damage was evaluated using a standardized lung injury scoring system to obtain a histological score for lung injury. The results are shown in Fig. 9 As shown in the results, consistent with the in vitro data, the inhibitory concentration of forsythin on the mouse PIC model was lower than that on the LPS model. The total protein concentration, total cell number and TNF-α, IL-6 and IL1β levels in the alveolar lavage fluid of 0.1 mg / kg FPC administered intratracheally were significantly different from those of the model group (P<0.001). The anti-inflammatory effects were dose-dependent at doses of 0.02, 0.1 and 0.5 mg / kg, and the anti-inflammatory effects of 0.5 and 1 mg / kg were similar. Compared with the model group, the total protein concentration and total cell count in the alveolar lavage fluid of 1 mg / kg group were reduced by 60.16% and 44.11%, and the levels of TNF-α, IL-6, and IL1β in the alveolar lavage fluid were reduced by 64.69%, 56.60%, and 57.93%, respectively. However, at the same dose, the physical suspension administered by trachea only reduced the total protein concentration and total cell count in the alveolar lavage fluid by 11.48% and 14.73%, respectively, and the levels of TNF-α, IL-6, and IL1β in the alveolar lavage fluid were reduced by 14.73%. 6. The levels of IL1β were only reduced by 27.01%, 19.93%, and 23.07%, and there were significant differences between the two in all indicators (P<0.001). Compared with tracheal administration, the anti-inflammatory effect of FPC administered by oral gavage was weaker, but it was still better than FOR administered by oral gavage. Oral gavage of FPC reduced the levels of TNF-α and IL-6 by 33.83% and 44.57%, respectively, which was significantly better than the 15.27% and 0.69% of FOR administered by oral gavage (P<0.05). The protective effect of lung injury shown by the results of pathological sections was consistent with the results reflected by the above indicators. Therefore, similar to the LPS model, tracheally administered FPC still showed the best anti-inflammatory ability in the ALI model induced by PIC.
[0085] Experimental Example 7 Study on the Effect of Forsythiaside Phospholipid Complex (FPC, prepared in Example 2) Suspension (FPC) on the Survival Rate of LPS-Induced Acute Respiratory Distress Syndrome (ARDS) Mice
[0086] The present invention uses a mouse tracheal instillation of high-dose LPS to induce an ARDS model, and compares and evaluates the effects of FPC and forsythiaside FOR on the survival rate of mice after tracheal instillation and intraperitoneal administration. Specifically, the mice were divided into a normal saline control group (Ctrl), a model group (LPS), a dexamethasone positive control group (DEX), an FPC tracheal instillation group (IT-FPC), an FPC intraperitoneal injection group (IP-FPC), and a FOR intraperitoneal injection group (IP-FOR). Each mouse in the Ctrl group was given 50 μL of normal saline, the positive drug dexamethasone was administered at 5 mg / kg intraperitoneally, the FPC IT group was administered at a dose of 2 mg / kg, the IP group was administered at a dose of 20 mg / kg; the FOR IP group was administered at a dose of 20 mg / kg. Three hours after administration, LPS (600 μg / mouse) was instilled into the trachea of mice except the NS group. The survival of the mice was then observed every 12 hours and their weight was recorded. After 7 days of continuous observation and recording (168 hours), the mice were euthanized and part of their lung tissue was collected and fixed with tissue fixative for more than 24 hours. The tissue was then embedded in paraffin and sliced. The sections were then stained with HE and sealed. The sections were examined under a microscope and image acquisition and analysis were performed. The tissue damage was then evaluated using a standardized lung injury scoring system to obtain a histological score for lung injury. The survival curve obtained is shown in Figure 1. Fig.10 As shown in A, the results showed that the 7-day survival rate of the FOR intraperitoneal injection group in this ARDS model was only 30%, which was not significantly different from the model group (10%) (P>0.05), while the 7-day survival rate of the FPC intraperitoneal injection group was 40%, which was significantly different from the model group (P<0.05), indicating that compared with FOR, the improvement of FPC bioavailability is beneficial to the relief of ARDS symptoms in mice, and the survival rate of the FPC tracheal administration group was 60%, showing a better protective effect than the intraperitoneal injection group, and there was a significant difference compared with the model group (P<0.01). This may be due to the increase in the bioavailability and prolonged retention time of FPC in lung immune cells and lung tissues through tracheal administration, resulting in a stronger anti-inflammatory effect and the function of repairing lung epithelium. The weight of mice recovered faster after tracheal administration of FPC, which may be due to the advantages of small side effects and faster onset of pulmonary administration ( Fig.10 B). Pathological sections showed that mice given FPC via trachea had more significant improvements in alveolar wall thickening, pulmonary fibrosis, inflammatory cell infiltration, and alveolar hemorrhage than those in other groups, which was consistent with the survival rate ( Fig.10 C).
[0087] Experimental Example 8 Study on the Effects of Forsythiaside Physical Suspension (FOR) and Phospholipid Complex Suspension (FPC, Prepared in Example 2) on CYP-Induced Interstitial Cystitis (IC)
[0088] The present invention adopts rat intraperitoneal injection of high-dose CYP to induce IC model, and compares and evaluates the effects of FPC and forsythiaside FOR on rat bladder wall permeability and bladder edema after oral and intravesical administration. Specifically, the rats were divided into a normal saline control group (Ctrl), a model group (CYP), a FOR oral group (IG-FOR), an SPC-FPC oral group (IG-SPC-FPC), a DPPC-FPC intravesical administration group (IDD-DPPC-FPC), and an SPC-FPC intravesical administration group (IDD-SPC-FPC). Each rat was intraperitoneally injected with 150 mg / kg CYP to induce the IC model. 24 hours after modeling, except for the NS group, the FOR IG group was orally administered at 40 mg / kg, the FPC IG group was administered at a dose of 40 mg / kg, and the IDD group was administered at a dose of 2 mg / kg. Evans blue was used to measure the permeability of the bladder inflammation barrier 23 hours after administration. Specifically, 2% Evans blue dye (3 mL / kg) was injected into the tail vein. One hour after injection, the rats were euthanized. The bladders were removed, weighed, and incubated with 1 ml of formamide at 56°C overnight with shaking. The absorbance (620 nm) was measured using a spectrophotometer, and the content of Evans blue in bladder tissue was calculated as pg Evans blue / μg tissue, and the degree of bladder edema was assessed as mg of rat bladder weight / g of body weight. Fig.11 As shown, the results showed that the FPC intravesical administration group could reduce the Evans blue content in the bladder tissue of rats under the IC model, which was significantly different from the model group (CYP) (P<0.05), while the Evans blue content in the bladder tissue of rats in the FOR and FPC oral groups was not significantly different from that in the model group (P>0.05). This shows that compared with oral administration, intravesical administration is beneficial to improve the therapeutic effect of FPC on IC rats, with a certain significant difference compared with the model group (P<0.05), which may be due to the fact that intravesical administration can directly deliver the drug to the lesion site, so a smaller drug dose can be used to achieve the therapeutic effect.
Claims
1. A forsythiaside phospholipid complex, It is characterized in that The invention comprises forsythiaside and phospholipid, wherein the forsythiaside and the phospholipid are compounded through intermolecular non-covalent bonds, and the mass ratio of the forsythiaside to the phospholipid is 1:(1-10), preferably 1:(1-4); the forsythiaside phospholipid complex is prepared by the following method: forsythiaside and phospholipid are weighed at a mass ratio of 1:(1-10), preferably 1:(1-4), and an organic solvent is added to dissolve them, and then they are mixed evenly; compounding is carried out at a temperature of 30-60°C, and the reaction time is 0.5-4 hours, preferably 1.5-2.5 hours, and after the reaction is completed, cholesterol is added until dissolved, and then reduced pressure rotary evaporation is carried out, a redissolution solvent is added, and after filtering through an organic microporous filter membrane, rotary evaporation is carried out again, and vacuum drying is carried out to obtain the forsythiaside phospholipid complex.
2. The forsythiaside phospholipid complex according to claim 1, It is characterized in that The phospholipid is one of soybean lecithin, egg yolk lecithin, dipalmitoylphosphatidylcholine (DPPC), and distearoylphosphatidylcholine (DSPC); the organic solvent is a methanol-chloroform solution mixed in a volume ratio of 1:1; and the re-dissolving solvent is dichloromethane.
3. The forsythiaside phospholipid complex according to claim 1, It is characterized in that The mass ratio of cholesterol to phospholipids is 1:
2.
4. Use of the forsythiaside phospholipid complex according to any one of claims 1 to 3 in the preparation of a drug for treating interstitial cystitis or inflammation caused by viruses or bacteria in lung infections.
5. The use according to claim 4, It is characterized in that The medicine is an oral preparation, a suspension for local administration or an inhalable aerosol.
6. An oral preparation containing forsythiaside phospholipid complex, It is characterized in that The forsythiaside phospholipid complex according to any one of claims 1 to 3 is prepared into an oral preparation by conventional pharmaceutical techniques.
7. A suspension containing forsythiaside phospholipid complex, It is characterized in that Prepared by the following method: After the forsythiaside phospholipid complex described in any one of claims 1 to 3 is added to physiological saline or PBS for hydration, the particle size is controlled by ultrasonic dispersion, high-pressure homogenization, microfluidics and other particle size control methods, and then high-pressure sterilization or filtration is performed to form a forsythiaside phospholipid complex suspension.
8. The suspension according to claim 7, It is characterized in that The mass ratio of the forsythiaside phospholipid complex to physiological saline or PBS is 1:100; the particle size distribution range of the suspension of the forsythiaside phospholipid complex is 50-1000nm, and the median particle size range is 100-350nm, preferably 100-250nm.
9. An inhalable aerosol containing forsythiaside phospholipid complex, It is characterized in that The suspension of the forsythiaside phospholipid complex according to claim 7 or 8 is formed into an inhalable aerosol by an air compression nebulizer or a vibrating mesh nebulizer.
10. Use of the oral preparation according to claim 6, the suspension according to claim 7 or 8, or the inhalable aerosol according to claim 9 in the preparation of a medicament for treating interstitial cystitis or inflammation caused by viruses or bacteria in lung infections.
Citation Information
Patent Citations
Melatonin phospholipid complex, melatonintransdermal drug deliverypreparation and preparation method of melatonin phospholipid complex
CN104474551A
Anti-pro-oxidant / glyceryl octyl ascorbic acid derivative and its preparation and use
JP2017057146A
Highly stable particle composition containing ascorbic acid derivative
JP2021167286A
